CN114073711A - Application of tremella polysaccharide in preparation of preparation with effect of preventing and treating non-alcoholic fatty liver disease - Google Patents
Application of tremella polysaccharide in preparation of preparation with effect of preventing and treating non-alcoholic fatty liver disease Download PDFInfo
- Publication number
- CN114073711A CN114073711A CN202111625465.2A CN202111625465A CN114073711A CN 114073711 A CN114073711 A CN 114073711A CN 202111625465 A CN202111625465 A CN 202111625465A CN 114073711 A CN114073711 A CN 114073711A
- Authority
- CN
- China
- Prior art keywords
- tremella polysaccharide
- liver
- polysaccharide
- tremella
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 121
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 112
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 112
- 241001506047 Tremella Species 0.000 title claims abstract description 109
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 36
- 230000000694 effects Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 description 23
- 210000005228 liver tissue Anatomy 0.000 description 16
- 238000013518 transcription Methods 0.000 description 15
- 230000035897 transcription Effects 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 11
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 208000004930 Fatty Liver Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010019708 Hepatic steatosis Diseases 0.000 description 8
- 208000010706 fatty liver disease Diseases 0.000 description 8
- 150000004804 polysaccharides Polymers 0.000 description 8
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 229940118019 malondialdehyde Drugs 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229960001231 choline Drugs 0.000 description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004136 fatty acid synthesis Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004368 Modified starch Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 229930189775 mogroside Natural products 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
- 101150053603 HMGCR gene Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 108091022862 fatty acid binding Proteins 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 101150044508 key gene Proteins 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 208000004481 Choline Deficiency Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 108010086524 Hepatocyte Nuclear Factor 4 Proteins 0.000 description 1
- 108010049606 Hepatocyte Nuclear Factors Proteins 0.000 description 1
- 102000008088 Hepatocyte Nuclear Factors Human genes 0.000 description 1
- 102000015902 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
- 108050004132 Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- UBXYXCRCOKCZIT-UHFFFAOYSA-N biphenyl-3-ol Chemical group OC1=CC=CC(C=2C=CC=CC=2)=C1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000021752 choline deficiency disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of tremella polysaccharide in preparation of a preparation with effects of preventing and treating non-alcoholic fatty liver, wherein the tremella polysaccharide is derived from common food, has clear structural characteristics and controllable quality, and can effectively prevent and treat the non-alcoholic fatty liver. The average molecular weight of the tremella polysaccharide is 3 multiplied by 106Da to 4X 106Da, total sugar content 85-90 wt%, uronic acid content 15-20 wt%, and no protein and triple helix conformation.
Description
Technical Field
The invention belongs to the field of medical care, and particularly relates to tremella polysaccharide with a function of preventing and treating non-alcoholic fatty liver and application thereof.
Background
The pathology of Nonalcoholic Fatty Liver (NAFLD) is mainly characterized by excessive fat accumulation in the Liver, which in turn causes parenchymal steatosis in the Liver cells. If the control is not good, the disease can progress into steatohepatitis, hepatic fibrosis, liver cirrhosis, even liver failure or liver cancer with a high probability.
According to statistics, the incidence of NAFLD is increased year by year in China, about 1.5 hundred million patients with NAFLD are more than viral liver diseases at present, and the NAFLD becomes the liver disease with the highest incidence. The current generation mechanism of NAFLD is not completely obvious, and abnormal lipid metabolism, lipid peroxidation, insulin resistance, heredity, improper hormone use, environmental and adverse drug reactions and the like can participate in the generation or development of the NAFLD.
For the treatment of NAFLD, aerobic exercise is recommended at home and abroad, but recent studies have found that the lipid and blood lipid content of liver can be effectively reduced by physical exercise, but the treatment of drug is still needed because the drug is not repairable for damaged liver cells. For the clinical treatment of NAFLD, the current main treatment is to adopt a symptomatic treatment aiming at the etiology, generally the given medicines mainly improve the four types of insulin resistance, oxidation resistance, lipid-lowering medicines and anti-cytokine release medicines, but the problems of poor treatment effect, poorer prognosis, difficult persistence and easy relapse are prominent, and the toxic and side effects of the medicines are generated after long-term use. The traditional Chinese medicine has the characteristics of multiple targets and multiple ways, and also accumulates a great deal of experience in the aspect of treating NAFLD. The Chinese herbal medicine with homology of medicine and food has rich polysaccharide content, and in recent years, many scholars adopt polysaccharide substances to treat NAFLD, and find that the polysaccharide substances can play a role in treating NAFLD through mechanisms of regulating blood fat, promoting oxidation and synthesis of fatty acid, resisting oxidation, improving insulin resistance, improving liver function and the like. However, the polysaccharide-based traditional Chinese medicine formula has the problems of difficult guarantee of efficacy and unclear action mechanism due to unclear effective ingredients and uncontrollable quality, and the like, so that the application is limited.
The existing research shows that the main action mechanisms of the polysaccharides with different structures for treating NAFLD are different, and the effect difference is huge. Because the polysaccharide structures from different sources and structures are various, and the biological activity and the action mechanism are possibly different, the search for the food-borne polysaccharide which has obvious curative effect, controllable quality, clear mechanism, high quality of food sources, low cost and high safety and is important for the development and utilization of the polysaccharide and the prevention and treatment of fatty liver.
Disclosure of Invention
In view of the above, the invention provides an application of a specific tremella polysaccharide in preparation of a preparation with a function of preventing and treating non-alcoholic fatty liver.
The invention provides an application of tremella polysaccharide in preparation of a preparation with effects of preventing and treating non-alcoholic fatty liver, wherein the average molecular weight of the tremella polysaccharide is 3 multiplied by 106Da to 4X 106Da, total sugar content 85-90 wt%, uronic acid content 15-20 wt%, and no protein and triple helix conformation.
In the application, preferably, the average molecular weight of the tremella polysaccharide is 3.59 multiplied by 106Da, total sugar content 89.5 wt%, uronic acid content 19.3 wt%, and no protein and triple helix conformation.
In the use, the preparation may be a food or a pharmaceutical. The food can be health food, functional food, food for special medical use, and food for the elderly for preventing and treating non-alcoholic fatty liver.
Further, the food may be in the form of a beverage, powder, tablet, capsule, gel candy, extract, or the like.
The preparation can also be added with required auxiliary materials, such as mogroside, maltodextrin, sucralose, lactose, modified starch, pregelatinized starch, magnesium stearate, high fructose syrup, citric acid, sodium citrate and the like, so as to meet the requirements of specific dosage forms or mouthfeel and the like.
The invention also provides a food, which contains the tremella polysaccharide, and the average molecular weight of the tremella polysaccharide is 3 multiplied by 106Da to 4X 106Da, total sugar content 85-90 wt%, uronic acid content 15-20 wt%, and no protein and triple helix conformation. Preferably, the average molecular weight of the tremella polysaccharide is 3.59 × 106Da, total sugar content 89.5 wt%, uronic acid content 19.3 wt%, and no protein and triple helix conformation.
The invention also provides a composition with the efficacy of preventing and treating the non-alcoholic fatty liver disease, wherein the active ingredients in the composition comprise tremella polysaccharide; optionally, the composition also comprises auxiliary materials; wherein the average molecular weight of the tremella polysaccharide is 3 × 106Da to 4X 106Da, total sugar content 85-90 wt%, uronic acid content 15-20 wt%, and no protein and triple helix conformation; preferably, the average molecular weight of the tremella polysaccharide is 3.59 multiplied by 106Da, total sugar content 89.5 wt%, uronic acid content 19.3 wt%, and no protein and triple helix conformation. The tremella polysaccharide (Dr) added in the present invention is commercially available, for example, from polysaccharide doctor Biotechnology (Guangzhou) Ltd.
Tremella polysaccharide).
In some embodiments, the active ingredient in the composition is the tremella polysaccharide described above.
The technical scheme provided by the invention has the following beneficial effects:
the invention provides the specific tremella polysaccharide and the product thereof, wherein the specific tremella polysaccharide is derived from common food, has clear structural characteristics, controllable quality and clear mechanism, and can effectively prevent and treat the non-alcoholic fatty liver. Specifically, the structural characteristics of the active ingredient, namely the specific tremella polysaccharide are clear, the quality can be controlled, so that the efficacy is ensured, the problems of unstable efficacy, unclear quality control target and the like caused by the prevention and treatment of NAFLD (NAFLD) by a complex formula are solved, and the technical level is greatly advanced in similar solutions; secondly, the tremella polysaccharide regulates and controls the expression of a large amount of enzymes, transporters and proteins related to fatty acid metabolism and apolipoprotein synthesis by regulating the transcription level of fatty acid synthesis and fat transport related genes in the liver and the transcription level of a transcription factor HNF4 alpha which is very critical in hepatocyte differentiation and function maintenance, so as to reduce the level of non-alcoholic fatty liver caused by abnormal diet.
Drawings
FIG. 1 is a UV scanning spectrum of WSK Tremella polysaccharide (A) and example Tremella polysaccharide (B);
in FIG. 2, graph A is a molecular weight-retention time standard curve, graph B is a WSK Tremella polysaccharide gel chromatogram, graph C is a Tremella polysaccharide gel chromatogram of the embodiment of the invention, and graph D is Congo red analysis;
FIG. 3 is a staining chart of liver tissue sections of experimental animals: a is blank group, B is model group, C is example tremella polysaccharide group, and D is WSK tremella polysaccharide group.
Detailed Description
To facilitate an understanding of the invention, the invention will now be described more fully with reference to the accompanying drawings. Preferred embodiments of the present invention are shown in the drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The detection methods referred to herein are all conventional in the art, and nothing specifically stated is what a person skilled in the art would understand or know from the current state of the art or common general knowledge.
Some of the starting materials used in the examples or comparative examples are described below:
examples Tremella polysaccharide powder (high purity Tremella polysaccharide, available from polysaccharide Boshi Biotech (Guangzhou) Co., Ltd.), WSK Tremella polysaccharide (high purity Tremella polysaccharide, available from Shanghai Huiwen Biotech Co., Ltd.), mogroside (50 wt% from Hunan Lvjin Co., Ltd.), maltodextrin (DE12 type, available from Shandong bowling Bao Co., Ltd.), sucralose (available from Guangdong Guangyi Qingqing Co., Ltd.), lactose (available for tableting, available from Rogat Co., Ltd.), modified starch (RS2 type, available from national starch Co., Ltd.)
The analysis of the structural properties of the example tremella polysaccharides and WSK tremella polysaccharides is illustrated below:
the method comprises the following steps: detecting the total sugar content by adopting a sulphuric acid phenol method, and taking mannose as a reference substance; the molecular weight is determined by HPGPC (high-Performance gel chromatography) method, and Tremella polysaccharide is extracted with 0.02mol/L KH2PO4The buffer solution (which is also a solution for mobile phase) was prepared to 2 mg. multidot.mL-1Filtering with 0.45 μm filter membrane, and detecting with chromatography system: the gel column is an Ultrahydrogel 1000 (7.8X 300mm) and an Ultrahydrogel 500 (7.8X 300mm) used in series, the flow rate is 0.8mL/min, and the column temperature is 35 ℃. The content of uronic acid is determined by m-hydroxy biphenyl method, and glucuronic acid is used as reference substance. The protein and nucleic acid content detection adopts ultraviolet scanning with the wavelength of 200-400 nm: dissolving the tremella polysaccharide into 1mg/mL solution by using deionized water. The conformation of two kinds of tremella polysaccharides in the solution is detected by adopting a Congo red method: dissolving the tremella polysaccharide into 1mg/mL solution by using deionized water, adding 2.0mL of 100 mu mol/L Congo red reagent, shaking up, gradually adding 4M NaOH, mixing for 10 minutes, determining the maximum absorption wavelength, and taking Yeast beta-glucan (Yeast beta-glucan) as a positive control.
As a result: in the examples, the total sugar (dry weight) content of the tremella polysaccharide and the WSK tremella polysaccharide is 89.5 percent and 91.2 percent respectively; the content of uronic acid (dry weight) is 19.3% and 20.2%, respectively, which indicates that the two tremella polysaccharides have high purity, and both of them belong to high-purity tremella polysaccharides. Examples Tremella polysaccharide and WSK Tremella polysaccharide solutions have no obvious absorption peak at 260nm and 280nm, which indicates that the two Tremella polysaccharide samples do not contain nucleic acid and protein substances, and refer to FIG. 1, wherein, graph A corresponds to WSK Tremella polysaccharide, and graph B corresponds to Tremella polysaccharide of examples.
For the molecular weight determination, the standard curve of different molecular weights and retention times is shown in FIG. 2A, and the fitting equation is Log M-21.1774-1.8386X1+0.748X2-0.0012X3,R20.9983(X is retention time, min). Referring to fig. 2B and 2C, the two tremella polysaccharides exhibit similar polysaccharide molecular weight distributions, with the large peak being the tremella polysaccharide and the small peak being the solvent peak. The retention time corresponding to the peak tip is 14.942min and 13.433min respectively, and the average molecular weight Mw of the tremella polysaccharide obtained in the example is 3.59 multiplied by 10 according to the calculation software of the molecular weight of gel chromatography6Da, WSK Tremella polysaccharide average molecular weight Mw is 10.83 × 106Da, the molecular weights of both are about 2-fold different (FIG. 2B, C). Referring to fig. 2D, congo red analysis shows that the positive control, the Yeast β -glucan-congo red solution, with increasing NaOH concentration, has the characteristic feature of a triple-helix structure in which the maximum absorption wavelength increases first and then decreases, while the maximum absorption wavelengths of both tremella polysaccharide-congo red solutions decrease slowly with increasing NaOH concentration without increasing the absorption wavelength (fig. 2D), thereby indicating that both tremella polysaccharides do not have a triple-helix structure in the solution.
Example 1
Taking 100g of tremella polysaccharide powder, adding 100L of purified water and 10g of mogroside, stirring for dissolving, homogenizing and sterilizing to prepare the tremella polysaccharide beverage.
Example 2
Taking 100g of tremella polysaccharide powder, crushing, sieving with a 100-mesh sieve, adding 200g of maltodextrin and 0.1g of sucralose, uniformly mixing, adding 30mL of 50% ethanol aqueous solution, uniformly stirring, granulating, drying in an oven at 60 ℃, and then grading on a 30-mesh sieve to obtain tremella polysaccharide powder.
Example 3
Taking 1000g of tremella polysaccharide powder, crushing, sieving with a 100-mesh sieve, adding 500g of maltodextrin, 500g of lactose and 100g of modified starch, putting into a high-speed granulator, uniformly mixing, then adding 300mL of 50% ethanol, shearing, granulating, drying at 60 ℃ until the water content is less than 7.0 wt%, granulating with a 20-mesh sieve, then adding 0.1 wt% magnesium stearate, mixing, and tabletting to obtain the tremella polysaccharide tablet.
Example 4
Taking 1000g of tremella polysaccharide powder, crushing, sieving with a 60-mesh sieve, adding 500g of pregelatinized starch and 500g of maltodextrin, putting into a high-speed granulator, uniformly mixing, adding 400mL of 70% ethanol, shearing, granulating, drying at 60 ℃ until the water content is less than 10.0 wt%, granulating with a 20-mesh sieve, adding 0.1 wt% of magnesium stearate, mixing, filling into capsules, and preparing into tremella polysaccharide capsules.
Example 5
Adding 50g of Tremella polysaccharide powder into 2500g of purified water, stirring to dissolve completely, adding 20g of gelatin into purified hydrosol completely, adding 70g of fructose-glucose syrup, adjusting pH to 3.8 with citric acid and sodium citrate, decocting, mixing, degassing, casting, cooling, and demolding to obtain the Tremella polysaccharide soft candy.
Example 6
Efficacy verification of tremella polysaccharide for preventing and treating non-alcoholic fatty liver disease
Firstly, experimental samples: examples tremella polysaccharide, WSK tremella polysaccharide.
Second, efficacy experiment of tremella polysaccharide for preventing and treating non-alcoholic fatty liver disease
2.1 Experimental methods:
after 2 weeks acclimation, the mice (SPF-grade KM mice) were randomly divided into 4 groups (10 per group) by body weight: blank control group (normal group), methionine choline deficient feed modeling group (model group), methionine choline deficient feed + example tremella polysaccharide group (or S tremella polysaccharide group), methionine choline deficient feed + WSK tremella polysaccharide group (or WSK group). After the experiment, normal groups ingest normal feed and drink water freely, the other groups of mice feed methionine choline-deficient feed and drink water freely, and except for the model group, the experimental group gavage experimental samples (the dose of each group is 100mg/kg day) are taken once a day for 5 weeks continuously, wherein the dose of each group is equal to that of the distilled water with the same volume. After the last gastric lavage, all groups of mice are fasted and not forbidden for 12 hours, blood is taken from orbital venous plexus after anesthesia, serum is separated, and triglyceride TG and total cholesterol TC concentrations, glutamic-pyruvic transaminase ALT and glutamic-oxalacetic transaminase AST enzyme activities are measured according to the operation instructions of a kit (triglyceride TG measuring kit, total cholesterol TC measuring kit, alanine transferase ALT kit and glutamic-oxalacetic transaminase AST kit purchased from Nanjing Biotech). After blood was taken, the mice were sacrificed by cervical dislocation, and the intact liver was peeled off, washed with physiological saline, weighed and observed to record the appearance of the liver. Randomly selecting proper amount of liver tissue, fixing in tissue fixing solution, and storing the rest liver tissue in refrigerator at-80 deg.C. A proper amount of liver tissue fixed in the tissue fixing solution is taken, is sliced (the thickness is about 4 mu m) after being embedded by conventional paraffin, is stained by HE and oil red O respectively, and is placed under a microscope to observe the pathological changes.
Homogenizing a certain amount of liver tissue with a homogenizer, centrifuging at 4 deg.C and 5000rpm, collecting supernatant, quantifying protein (BCA protein quantification kit, purchased from Beijing kang, century Biotechnology Co., Ltd.), and measuring SOD enzyme activity and MDA concentration according to the kit (Total superoxide dismutase (SOD) determination kit, Malondialdehyde (MDA) kit, purchased from Nanjing, Bio-technology Co., Ltd.).
Taking a certain amount of liver tissue, adding lysate to extract total RNA, carrying out reverse transcription to obtain cDNA, detecting the transcription level of HMCGR (hydroxymethyl glutaryl-coenzyme A reductase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase by qPCR (quantitative polymerase chain reaction), wherein the sequences of the used primers are F-GAATTGAACTCCCCATCGAG, R-GGATATGCTTGGCATTGACC), FABP (Fatty acid binding protein, fat acid-binding protein, and the sequences of the used primers are F-ATGAACTTCTCCGGCAAGTACC, R-GGTCCTCGGGCAGACCTAT), ACC (Fatty acid synthesis rate-limiting enzyme, Acetyl-CoA carboxylase, and the sequences of the used primers are F-CTGGAGGCCTTGCCACTGTA, R-GCTTGCACCAACACTCAGTTGAC), HNF4 alpha (hepatocyte nuclear factor 4 alpha, hepatocyte nuclear factor transcription factor, and the sequences of the used primers are F-CCGGGTGTCAGGAACAGTTG, R-TGCAGGACAGTCTGAGCCATC) genes, and taking beta-actin as internal reference (F-36 AAATCGTGCGTGACATCAAA, R-AAGGAAGGCTGGAAAAGAGC).
2.2, data statistics
Data are expressed as means ± SD, statistical analysis was performed using SPSS22.0 software, and group comparisons were analyzed using ANOVA with p <0.05 representing significant differences.
2.3, results of the experiment
The liver wet weight range of the normal group is 2.2 +/-0.4 g, the liver wet weight range of the model group is 3.5 +/-0.5 g, and the liver wet weight range has a remarkable increase compared with the liver wet weight range of the normal group (p is less than 0.05). The liver wet weight range of the S tremella polysaccharide group is 2.5 +/-0.6 g (compared with the model group, p is less than 0.05), and the liver wet weight range of the WSK group is 2.9 +/-0.5 g (compared with the model group, the statistical difference is avoided), which indicates that the tremella polysaccharide in the example has the effect of reducing the liver weight.
Representative staining of liver tissue sections from each group of mice is shown in FIG. 3, with white fat particles. The normal group of hepatocytes was well-aligned and normal in morphology (fig. 3A), and it can be seen from fig. 3B that the hepatocytes in the model group of animals were not uniformly distributed, contained a large amount of fat particles, and the liver tissues were severely fattened. In fig. 3C, it can be seen that the hepatocytes of the S tremella polysaccharide group are regularly arranged and mostly normal in morphology, and the fat particles are sporadically distributed in the liver tissue, indicating that the tremella polysaccharide of the example significantly improves the fatty liver. In fig. 3D, it can be seen that the liver tissue adiposity degree in the WSK group is improved (white fat particles are reduced) compared to the model group, but the improvement effect is greater compared to the tremella polysaccharide group of the example (fig. 3C). Thus, it is shown that the example tremella polysaccharide has the effect of reducing the proportion of fat in non-alcoholic fatty liver.
The serum biochemical indicators were further analyzed and the results are shown in table 1 below. As can be seen from Table 1, TC, TG, ALT and AST in the model group are obviously increased (p is less than 0.05, and p is less than 0.01), which indicates that the lack of feed for methionine and choline causes the increase of blood lipid level and serious damage of liver cells of mice. The example shows that the tremella polysaccharide (S tremella polysaccharide group) can reduce blood lipid level and reduce liver cell damage (p is less than 0.05, and p is less than 0.01), and the WSK tremella polysaccharide (WSK group) also has a certain liver cell protection effect (p is less than 0.01), but the blood lipid reducing effect is not obvious. The overall data show that the liver cell protection and blood fat reduction effects of the tremella polysaccharide are better than those of the WSK tremella polysaccharide, and the structure of the tremella polysaccharide plays an important decisive role in the polysaccharide efficacy.
TABLE 1 serum Biochemical index (mean. + -. SD) for each group
P <0.05, p <0.01, compared to normal group; # p <0.05, # p <0.01, compared to model group; a p <0.01, compared to WSK group
The results of key gene transcript levels in liver tissues of each group of mice are shown in table 2. Hydroxymethyl glutaryl coenzyme A reductase (HMGCR) is a key enzyme for catalyzing the de-novo synthesis of cholesterol in vivo, and the activity directly influences the speed of cholesterol synthesis and the content of cholesterol in vivo. As can be seen from table 2, the HMGCR gene was significantly elevated in the model group transcript level (p <0.01), and both the example tremella polysaccharide and WSK tremella polysaccharide reduced the transcript level of the HMGCR gene but had no statistical difference. Fatty acid binding protein FABP is intracellular fatty acid carrier protein, the tremella polysaccharide remarkably regulates the transcription level of FABP (p is less than 0.01) in the embodiment, the synthesis level of fatty acid carrier protein in liver cells is enhanced, and WSK tremella polysaccharide has no obvious effect on the gene transcription regulation, so that the tremella polysaccharide in the embodiment is beneficial to transporting fat synthesized by liver cells out of liver by improving the synthesis of carrier protein, and the liver fat conversion level is reduced. ACC is a fatty acid synthesis rate-limiting enzyme, and its increased gene expression can promote fat synthesis. The transcription level of the gene in the model group is remarkably improved (p <0.01), while the example tremella polysaccharide reduces the transcription level of ACC (p <0.05), but the effect of WSK tremella polysaccharide is not obvious, which suggests that the example tremella polysaccharide is helpful for reducing the synthesis of fat in liver. HNF4 α is an important transcription factor of liver, regulates the expression of various liver genes, and has a decisive effect on the characteristics of hepatocytes and liver functions, and HNF4 α regulates the expression of a large number of enzymes, transporters and proteins involved in fatty acid metabolism and apolipoprotein synthesis. The transcriptional level of HNF4 alpha in the model group is obviously reduced (p <0.05), which indicates that the overall transcriptional activity of HNF4 alpha is reduced, and the expression level of mRNA of genes downstream of HNF4 alpha, such as ApoB and MTTP, is reduced, so that VLDL assembly and secretion are hindered, a large amount of triglyceride is accumulated in the liver and cannot be discharged outside, and the development of fatty liver is further promoted. Therefore, increasing the transcription level of HNF4 alpha in liver tissue helps to reduce the development of fatty liver. The example shows that the tremella polysaccharide obviously improves the transcription level of HNF4 alpha (p is less than 0.05), but the WSK tremella polysaccharide has no obvious regulation effect on the transcription level of HNF4 alpha; therefore, it is presumed that the elevated level of HNF4 α transcription contributes to the reduction of fatty liver level.
In conclusion, the tremella polysaccharide can reduce the level of fat content in the liver by reducing the transcription of genes related to fatty acid synthesis of the liver and promoting the transcription of genes related to fat transfer, delay the development of the fatty liver, and reverse the lipid metabolism abnormality in the nonalcoholic fatty liver by regulating the transcription level of the liver core function gene HNF4 alpha, thereby having the effect of preventing and treating the fatty liver. Particularly, the WSK tremella polysaccharide has no obvious effect on regulation of genes related to liver fat metabolism, and the characteristic structure of the tremella polysaccharide has a decisive effect on the prevention and treatment of the activity of the non-alcoholic fatty liver.
TABLE 2 Key Gene transcript levels (fold-changed) in liver tissue of groups of mice (mean. + -. SD)
P <0.05, p <0.01, compared to normal group; # p <0.05, comparison with model group
The SOD activity and MDA concentration in liver tissues are detected, and the results are shown in Table 3, compared with the normal group, the model group has the advantages that the SOD activity is reduced, and the MDA concentration is increased (p is less than 0.05); compared with a model group, the two tremella polysaccharides improve SOD enzyme activity and reduce the concentration of MDA (p is less than 0.05), however, the action effects of the tremella polysaccharides and the WSK tremella polysaccharides in the examples are not obviously different, which indicates that the alleviating effect of the tremella polysaccharides in the examples on the fatty liver of an experimental animal is not realized by improving the antioxidant activity in liver tissues.
TABLE 3 SOD Activity and MDA concentration (mean + -SD) in liver tissue of each group of mice
P <0.05, compared to normal group; # p <0.05, comparison with model group
The experimental data show that the tremella polysaccharide with the characteristic structure (example tremella polysaccharide) can reduce blood fat, protect damaged liver cells and reduce the accumulation of fat in liver cells in a non-alcoholic fatty liver disease mouse model induced by methionine choline deficiency through regulating and controlling the transcription level of genes related to fat metabolism in the liver, so that the tremella polysaccharide has the effect of preventing and treating non-alcoholic fatty liver disease.
What has been described above is merely the principles and preferred embodiments of the present application. It should be noted that, for those skilled in the art, the embodiments obtained by appropriately combining the technical solutions respectively disclosed in the different embodiments are also included in the technical scope of the present invention, and several other modifications may be made on the basis of the principle of the present application and should be regarded as the protective scope of the present application.
Claims (7)
1. The application of the tremella polysaccharide in preparing the preparation with the effect of preventing and treating the non-alcoholic fatty liver is characterized in that the average molecular weight of the tremella polysaccharide is 3 multiplied by 106Da to 4X 106Da, total sugar content 85-90 wt%, uronic acid content 15-20 wt%, and no protein and triple helix conformation.
2. The use according to claim 1, wherein the tremella polysaccharide has an average molecular weight of 3.59 x 106Da, total sugar content 89.5 wt%, uronic acid content 19.3 wt%, and no protein and triple helix conformation.
3. Use according to claim 1 or 2, wherein the formulation is a food or a medicament.
4. Use according to claim 3, wherein the food product is in the form of a beverage, powder, tablet, capsule, gel candy or extract.
5. A food product comprising the Tremella polysaccharide of any one of claims 1-4.
6. A composition with the efficacy of preventing and treating non-alcoholic fatty liver disease, wherein the active ingredients in the composition comprise the tremella polysaccharide as claimed in any one of claims 1-4; optionally, the composition further comprises an auxiliary material.
7. The composition with the effect of preventing and treating the non-alcoholic fatty liver disease as claimed in claim 6, wherein the active ingredient in the composition is the tremella polysaccharide as claimed in any one of claims 1 to 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111625465.2A CN114073711A (en) | 2021-12-28 | 2021-12-28 | Application of tremella polysaccharide in preparation of preparation with effect of preventing and treating non-alcoholic fatty liver disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111625465.2A CN114073711A (en) | 2021-12-28 | 2021-12-28 | Application of tremella polysaccharide in preparation of preparation with effect of preventing and treating non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114073711A true CN114073711A (en) | 2022-02-22 |
Family
ID=80284362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111625465.2A Pending CN114073711A (en) | 2021-12-28 | 2021-12-28 | Application of tremella polysaccharide in preparation of preparation with effect of preventing and treating non-alcoholic fatty liver disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114073711A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006076841A1 (en) * | 2005-01-18 | 2006-07-27 | Shanghai Wenda Biotech Inc. | Tremella heteropolysaccharides, its extractives, preparation method and uses of the same |
| CN107056960A (en) * | 2017-05-09 | 2017-08-18 | 河北韩美生物科技有限公司 | A kind of tremella polysaccharides and preparation method thereof |
| CN107446825A (en) * | 2017-09-11 | 2017-12-08 | 华熙福瑞达生物医药有限公司 | One plant of white fungus bacterial strain and its application |
-
2021
- 2021-12-28 CN CN202111625465.2A patent/CN114073711A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006076841A1 (en) * | 2005-01-18 | 2006-07-27 | Shanghai Wenda Biotech Inc. | Tremella heteropolysaccharides, its extractives, preparation method and uses of the same |
| CN107056960A (en) * | 2017-05-09 | 2017-08-18 | 河北韩美生物科技有限公司 | A kind of tremella polysaccharides and preparation method thereof |
| CN107446825A (en) * | 2017-09-11 | 2017-12-08 | 华熙福瑞达生物医药有限公司 | One plant of white fungus bacterial strain and its application |
Non-Patent Citations (2)
| Title |
|---|
| 张艳;王爽;李永哲;刘奔;宋爽;: "基于代谢组学方法研究银耳多糖对非酒精性脂肪肝大鼠的干预作用" * |
| 陈新仁;吴琼;郑成;: "银耳多糖的分子修饰及抗氧化作用的研究" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395563A (en) | Application of oligoguluronic acid and derivative thereof in preparation of drugs and health products used for preventing and treating hyperlipidemia and complications thereof | |
| CN112603923A (en) | Application of phillyrin in preparation of medicine for preventing or/and treating type II diabetes | |
| EP3574912B1 (en) | Composition for treating diabetic disease | |
| CN114073711A (en) | Application of tremella polysaccharide in preparation of preparation with effect of preventing and treating non-alcoholic fatty liver disease | |
| JP2021512997A (en) | Separated windproof polysaccharides and their uses | |
| CN105535152B (en) | Application of loquat leaf total sesquiterpene extract | |
| KR20090091615A (en) | Tetracera scandens extracts and 4h-chromen-4-one derivatives isolated therefrom increasing glucose uptake in differentiated l6 muscle cells | |
| KR100473530B1 (en) | Composition containing an extract of sopungsungi-won crude drug complex for preventing and treating diabetes mellitus | |
| CN112587573A (en) | Application of Zhuang medicine-Wuye alcohol extract in preparation of anti-hyperuricemia medicine | |
| CN113350453A (en) | Health composition for raising HDL-C | |
| CN103432124B (en) | The application of oxymatrine in preparation control medicine for treating diabetic nephropathy | |
| CN108379455B (en) | Uric acid reducing composition | |
| CN102920737B (en) | Bee pollen water extract buccal tablet used for preventing alcoholism | |
| KR100473531B1 (en) | Composition containing an extract of truncated sopungsungi-won crude drug complex for preventing and treating diabetes | |
| CN111019010A (en) | Nigella sativa seed polysaccharide, extraction method and application in preparation of medicament for treating type 2 diabetes | |
| CN110314160A (en) | Berbamine prevents and treats the application in medicine for treating diabetic nephropathy in preparation | |
| CN117045629B (en) | Application of cortex lycii radicis-element in medicine for treating kidney stones | |
| CN102526203B (en) | Preparation method of Chinese toona fruit extract with diabetic nephropathy resistance effect | |
| US20090304822A1 (en) | Extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum and compositions for improving metabolic syndrome | |
| CN116210900B (en) | Plant polyphenol sustained-release composition for regulating xanthine oxidase activity and accurate nutrient and preparation method thereof | |
| CN102935108B (en) | Pollen pini water extract enteric-coated tablet for alleviating hangovers | |
| AU2021105462A4 (en) | Use of fructus corni nano-powder in resisting type 2 diabetes mellitus | |
| CN115887477A (en) | Combined medicine for treating kidney disease hypertension | |
| KR20230174959A (en) | A composition for postprandial anti-hyperglycemia comprising red ginseng extract with high content of Amadori compound | |
| CN112480196A (en) | Hypoglycemic component in camellia bee pollen and extraction method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |